The abstract is read at the publisher; the summary is JClub's.
Acyl-eCR synthetic bromodomain cell lines enable quantitative in-cell target engagement profiling, using flow cytometry to measure inhibitor effects on chromatin binding and PROTAC-driven degradation.
- Why it matters: Drug development is slowed by the lack of high-throughput cellular assays that directly measure target engagement and off-target binding in living cells.
- What they did: The study engineered a panel of cell lines expressing Acyl-eCRs and built two flow cytometry assays: a competitive binding readout via PROTAC-induced degradation and a nuclear retention assay for chromatin displacement.
- The result: Acyl-eCRs reproduce inhibitor and PROTAC responses seen with endogenous bromodomain proteins, enabling scalable, physiologically relevant potency and specificity assessment without protein purification or in vitro characterization.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.